GSK stock extends lower as sellers maintain control over price action

Traders Union
All News
Stocks
GSK drops 2.33% today to GBX1,846

Highlights

GSK Pharma stock reported standalone Q2 profit up 31% at Rs 334.62 crore, driven by stronger sales and improved revenue.
Results were supported by a Rs 42.09 crore tax-refund interest, boosting quarterly profit alongside operational gains.
GSK Pharma stock trades below key moving averages with strong selling pressure; price expected to fluctuate within GBX1,796 to GBX1,895 and a bearish scenario is more likely.

Profit and revenue gains offset by persistent selling in shares

GSK Pharma reported a significant rise in its standalone Q2 profit, which increased by 31% to reach Rs 334.62 crore, reflecting both robust sales momentum and a 21% improvement in revenue. The bottom line was further supported by the addition of Rs 42.09 crore in tax-refund interest, contributing to the quarter's positive financial outcome. While these results highlight improved operational and non-operating performance, price action has remained under broader selling pressure.

Oversold oscillator meets seller strength as resistance holds

On the hourly chart, GSK trades below the MA-20, MA-50, and the long-term MA-200, illustrating sustained downward momentum through multiple timeframes. The Ichimoku Kijun sits at GBX1,858, serving as immediate resistance. Among momentum indicators, MACD signals a strong buy, while ADX is neutral. RSI and CCI are both in neutral territory, but Stochastic RSI is oversold, hinting at possible short-term rebound potential. Bull/Bear Power stays negative, underscoring ongoing seller dominance, and the Awesome Oscillator remains neutral. The alignment of an oversold Stochastic RSI with seller momentum via Bull/Bear Power reflects a tug-of-war between technical rebound potential and persistent pressure.

Downward bias persists unless breakout surpasses volatility band

In the coming days, GSK is expected to consolidate within the volatility band of GBX1,796 to GBX1,895. There is a 32% chance of a rebound above resistance, while the prevailing scenario—a 68% likelihood—involves continued movement toward the lower end of the range. A bullish breakout would require a clear close above the Ichimoku Kijun and GBX1,895, while a bearish scenario could see the price slipping below GBX1,796.

Viktoras Karapetjanc, expert at Traders Union, notes that GSK delivered a strong Q2 profit, underpinned by both core revenue growth and a material boost from tax-refund interest. He sees robust fundamentals providing support despite the current technical downward pressure. The analyst believes that broader market sentiment is still weighing on the stock, but better earnings quality enhances the longer-term outlook. 'With fundamentals improving, any reversal above the GBX1,858–1,895 resistance band could quickly restore bullish momentum for GSK,' he says.

Earlier, analysts noted that GSK exhibited near-term technical strength but continued to face longer-term resistance. The current analysis signals that despite improved financial performance, ongoing downside momentum warrants close monitoring of the GBX1,796 support for potential further weakness.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.